Effects of Bosentan on Morbidity and Mortality in Patients With Idiopathic Pulmonary Fibrosis - a Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Group Sequential, Phase III Study.
BUILD 3 is a prospective, multicenter, randomized, double-blind, parallel group,
placebo-controlled, event-driven, group sequential, phase III superiority study. The
primary objective is to demonstrate that bosentan delays disease worsening or death in
patients with Idiopathic Pulmonary Fibrosis.
Study Status: Completed
Idiopathic Pulmonary Fibrosis
Information provided by:
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
The Cleveland Clinic Foundation
Cleveland, Ohio 44195
Isabelle Leconte., Study Director